Business Wire

NY-THE-WE-COMPANY

15.5.2019 13:02:11 CEST | Business Wire | Press release

Share
The We Company Launches ARK A New Real Estate Acquisition & Management Platform

The We Company is pleased to announce the launch of ARK, its global real estate acquisition and management platform.

An Evolution of The We Company Real Estate Investment Strategy

ARK builds on the strong foundation in real estate acquisition and management represented by WeWork Property Advisors, an investment advisor affiliated with The We Company and Rhône Group and will combine with ARK as part of the launch.

ARK will focus on acquiring, developing, and managing real estate assets in global gateway cities and high-growth secondary markets that will benefit from WeWork’s occupancy. WeWork will deploy its space-as-a-service model in Ark owned or operated properties for our member companies, including our growing Enterprise business - now representing over 40% of global memberships - in conjunction with our anchor tenant strategy.

ARK will leverage its access to The We Company’s site selection process and proprietary technology, as well as its relationships with partners and enterprise member companies, to access a broad range of real estate opportunities. ARK intends to immediately stabilize assets by executing a proven pre-packaged business plan and will apply The We Company’s holistic solutions for real estate owners, based on The We Company’s established capabilities in sourcing, building, filling, and operating properties.

Rich Gomel, Managing Partner, ARK, said : “We have seen first hand the value that the WeWork ecosystem can create for landlords and real estate partners. The launch of ARK will help drive growth by leveraging The We Company’s extensive real estate experience and network. ARK has been set up to capitalize on that opportunity and allow us to provide different partnership options for the real estate community to participate in the growth and expansion of the We Company.”

Ivanhoé Cambridge - Strategic Partner

ARK is also pleased to announce that Ivanhoé Cambridge, a real estate subsidiary of Caisse de dépôt et placement du Québec and one of the world’s largest and most highly-respected institutional real estate investors, is providing substantial capital and support to the platform. Ivanhoé Cambridge plans to collaborate with ARK on its real estate acquisition and management of properties around the world, allowing the platform to benefit from Ivanhoé Cambridge’s significant experience and expertise in the real estate sector.

Sylvain Fortier, Chief Investment and Innovation Officer at Ivanhoé Cambridge said: “Like The We Company, we believe there is enormous upside in disrupting traditional norms of real estate. We share the same vision, commitment to social responsibility, and long-term approach towards real estate making this a natural partnership and one that we are confident will be transformational for both companies. The We Company brings its creative and innovative talent, along with its technological and design expertise, which are essential to meeting the new expectations of real estate spaces whether it is in the commercial or residential sphere. ARK brings a strong team of acquisition and asset management professionals and deep relationships with The We Company. I think we will complement each other beautifully.”

Management Team and Partners

ARK will initially deploy $2.9bn in total equity capital following its combination with WeWork Property Advisors. The We Company will be the majority owner of ARK.

The platform will be chaired by Steven Langman, Managing Director of Rhône Group and a member of The We Company’s Board of Directors. He will serve as Chairman of ARK’s Management Committee and will also serve on ARK’s investment committees.

In addition to Mr. Langman and Mr. Gomel, Wendy Silverstein, formerly of New York Reit and Vornado Realty Trust will serve as ARK’s Chief Investment Officer. ARK’s leadership is supported by a dedicated group of experienced real estate professionals with diverse expertise across real estate acquisition, development, and management.

About :

The We Company

Founded by Adam and Rebekah Neumann and Miguel McKelvey in 2010, The We Company comprises three distinct business lines - WeWork, WeLive, and WeGrow - that further our mission to elevate the world’s consciousness. WeWork’s mission is to create a world where people work to make a life, not just a living; WeLive’s mission is to build a world where no one feels alone; and WeGrow’s mission is to unleash every human’s superpowers. The We Company began 2019 with 425 locations in 100 cities across 27 countries, and has over 400,000 members, which includes over 30% of the Fortune 500. For additional information, please visit www.we.co

ARK

ARK is an affiliate of The We Company and serves as its new global real estate acquisition and management platform based in New York City. ARK’s focus is acquiring, developing, and managing select real estate assets in global gateway cities and high-growth secondary markets. ARK collaborates with The We Company to apply The We Company’s existing, new, and developing products and methods of community and space management to ARK-owned real estate and leverage The We Company’s relationships with partners and enterprise member companies to create vibrant fully-programmed ecosystems.

Notes :

This press release may contain forward-looking statements, which should not be relied upon, and may be changed. Nothing contained in this press release should be relied upon as a promise, guaranty, or representation as to past or future performance of any company, entity, or vehicle or other targeted outcome. Actual events and conditions may differ materially.

The activities described in this press release entail a high degree of risk and no assurance can be given that The We Company’s or ARK’s or any of their affiliates’ objectives will be achieved. Any targeted objectives described in this press release are hypothetical in nature and based on current beliefs, assumptions, and information, and are shown for illustrative informational purposes only and not intended to forecast or predict future events, which are subject to significant economic, market and other uncertainties. Equity capital managed by ARK is in certain instances co-managed in collaboration with other third-party institutional managers and is subject to the terms and conditions set out in the various definitive agreements relating to that equity capital. Nothing contained in this press release constitutes an offer to sell nor does it seek an offer to buy securities, or an offer of investment advisory or investment management services, in any jurisdiction.

Neither The We Company, ARK, nor any of their affiliates makes any representation or warranty, express or implied, as to the accuracy or completeness of the information contained in this press release. This press release is not an offer to sell nor does it seek an offer to buy securities in any jurisdiction. Recipients of this press release are encouraged to contact the representatives of The We Company and ARK to discuss the procedures and methodologies (including assumptions) on which these statements are based, and should conduct their own independent investigation and assessment and seek independent advice as to the validity of the information contained in this press release and its implications in light of their own particular circumstances.

Contact:

Media Contact Dominic McMullan / Arif Shah press@wework.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye